President Trump's executive order recommending that the measles, mumps and rubella (MMR) vaccine be split up across three appointments is drawing poor reception from the pharmaceutical industry as drugmakers and trade groups say there's no scientific reasoning to follow the directive. The administration did not provide any new scientific data to support splitting up the...
President Trump's executive order recommending that the measles, mumps and rubella (MMR) vaccine be split up across three appointments is drawing poor reception from the pharmaceutical industry as drugmakers and trade groups say there's no scientific reasoning to follow the directive. The administration did not provide any new scientific data to support splitting up the...
<iframe src="https://statesidedaily.com/embed/cluster/52dee3174b6c0f2736e1df4e35ca8ef81e4166a1" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Drugmakers uninterested in Trump's order to split up MMR vaccine"></iframe>
